Recent News
Read ArticleThe striking propensity for gout flares to initiate at night has been recognised for centuries. In 1683, Thomas Sydenham famously observed that the typical patient "goes to bed and sleeps in good health" only to be awakened around 2:00 AM by excruciating pain.
Hip Replacement Advances
Hip replacement surgery has been a major advance in the management of patients with hip damage and diminishing quality of life. While this review provides new information regarding a new type of hardware (end of article), lets begin with a general overview.
Read Article
Retrospective study 1420 newly Dx non-tuberculous mycobacterial (NTM) infx (2012-2024) - 66 (4.6%) Dx w/ RA (55 after RA dx). Having RA + NTM incr risk of Resp. death (HR 4.3) w/ lower 5yr survival (75% vs 93%) partly explained by ILD and sytemic inflamm. https://t.co/6sdR7XwwD7
Dr. John Cush @RheumNow ( View Tweet)
What Lies Beneath - Uric Acid Deposition & Imaging https://t.co/j3dFhSPNlE
Links:
Dr. John Cush @RheumNow ( View Tweet)
In 2010 Colchicine fell under patent protection and price increased 16 fold, & out-of-pocket price increased 4.4-fold, colchicine use decreased 27%, while allopurinol, steroid & gout visits (ER, Rheum) increased. https://t.co/xyOxsnoM5z https://t.co/yoXehV0mPa
Dr. John Cush @RheumNow ( View Tweet)
CAR-T Therapy: EULAR 2026 Conference Recap
https://t.co/XALrMFReOe https://t.co/TK0ot8MZb6
Dr. John Cush @RheumNow ( View Tweet)
Do we need Better Strategies to Prevent Osteoporotic Fractures?
In a recent JAMA Viewpoints article, Dr. Susan Ott addresses several controversies in preventing osteoporosis (OP) related fractures.
https://t.co/YpmyZGCsjz https://t.co/NUkJVcxBjc
Dr. John Cush @RheumNow ( View Tweet)
Gout Cavalcade (7.10.2026)
Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week. July is Gout: More than Flares month.
https://t.co/I1zWdx9fzU https://t.co/EYQ3D9Z42t
Dr. John Cush @RheumNow ( View Tweet)
Guidelines to Spot Cancer in High Risk Dermatomyositis
MedPage Today
International guidelines can help identify dermatomyositis patients with a particularly high risk for cancer, according to a retrospective single-center U.S. study.
Read Article
Gout Imaging in Care
Gout is all about the crystals and the consequences of the disease are due to the inflammation they cause. Getting rid of urate crystals is the ultimate goal in gout, as we now know that it leads to the risk zero of flares and it normalizes the cardiovascular risk level of patients with gout.
Read Article
While not a validated Dx tool for gout, AI retinal scanning of digital fundus photography was tested on 107730 pts & showed high ROC - f NIDDM 0.833, Gout 0.832, OP 0.787, HTN 0.740, hyperlipidemia 0.736 & thyroid Dz 0.699 https://t.co/1yrlR04z4g https://t.co/c04YtVVERY
Dr. John Cush @RheumNow ( View Tweet)
RHEUMATOLOGIST SURVEY ON GOUT - In what percentage of your new Gout patients, do you do arthrocentesis and crystal ID? Answer here: https://t.co/jpebQev4VU
Dr. John Cush @RheumNow ( View Tweet)
RZV (Shingrix) response in 76 immunosuppressed SSc & 304 controls (CG) recv two RZV doses. High seroconversion seen in SSc but signif lower than CG (92.6% vs 99.7%, P 0.001), w/ lower concentration but comparable CMI, lower AE (74% vs 86%) https://t.co/ALlnVEZIAt https://t.co/kYYy2JIo2J
Dr. John Cush @RheumNow ( View Tweet)
20 yr. Tx trends in 6583 #SSc pts. 2005 to 2025 endothelin receptor antagonists & prostanoids/prostacyclins from 3% to 28%. CCB & PDE-5 inh stable. CTX shifted to mycophenolate, RTX, & nintedanib. Steriods decr from 50% to 18% https://t.co/nrm1Ov285f https://t.co/ftLn3bGH72
Dr. John Cush @RheumNow ( View Tweet)
Registration is now open!
Join Dr. Jack Cush as he moderates an expert discussion with Dr. Nicola Dalbeth, Dr. John Fitzgerald, and Dr. Sarah Tedeschi on the evolving role of imaging in gout.
Topics include:
🔹 Ultrasound
🔹 Dual-energy CT (DECT)
🔹 Crystal identification
🔹 https://t.co/iOOAAAEneX
Dr. John Cush @RheumNow ( View Tweet)
True or False: Extreme weight loss methods such as bariatric surgery and ketogenic diets may trigger gouty attacks, unlike GLP-1 agonist-induced weight loss.
Test your RheumIQ in this week's quiz at https://t.co/8BuwihOvfE.
Dr. John Cush @RheumNow ( View Tweet)
EMD Serono Announces FDA Breakthrough Therapy Designation for Enpatoran (TLR 7/8 inhibitors) for use in Cutaneous Lupus; based on the results from the Phase 2 WILLOW study https://t.co/TNM4whC0Qk https://t.co/70Cibg1gkW
Dr. John Cush @RheumNow ( View Tweet)
FDA - a 120Year History Protecting Americans. Nice overview.
- Began 1906 (as Bureau of Chemistry) w/ Pure Food & Drugs Act
- 1930 changed to Food and Drug Administration
- 1938 Food, Drug, and Cosmetics Act
- 1960s denied thalidomide approval https://t.co/3Ey98M9sxw My https://t.co/JS36EfJ19k
Dr. John Cush @RheumNow ( View Tweet)
DMARD Efficacy in RA-ILD
A network meta-analysis in the Journal of Autoimmunity reviews the pharmacologic options for rheumatoid arthritis–associated interstitial lung disease (RA-ILD). RA-ILD guidelines were recently presented by ERS/EULAR, but these were mainly conditional,
Dr. John Cush @RheumNow ( View Tweet)
New research shows synovial lining enriched in macrophages expressing SPP1 (encoding osteopontin) in proximity to fibroblasts and fibrin deposits. SPP1+ macrophages degrade fibrin & promote fibroblast proliferation that deposit collagen & does the damage, joint remodeling. A new https://t.co/yFxwAYFPPb
Dr. John Cush @RheumNow ( View Tweet)
Video
From the Blog
At first, it seemed similar to many other such sessions – a circle of folding chairs, a group of colleagues whose visages exuded understanding and acceptance – but this was special. I started the meeting…. “Hi, my name is Artie.”
Read Post
Podcasts
Gout QD clinics - lessons from the Clinic QD307-QD311
Gout Cavalcade (7.10.2026)
Gout Journal Club
Podcast Replay: Is it Time to Transition MOAs in RA?
Therapeutic Updates
Fundamentals of CAR T Cell Therapy and Its Investigational Use in Autoimmune Diseases
Sponsored By Bristol Myers Squibb
Learn more about the fundamentals of CAR T-cell therapy and its investigational use in autoimmune disease
Read Post
Watch our 'Systemic Burden of Gout' series as part of this month's Gout More than Flares campaign. Now available: 3 New Things It Pays to Know About Gout Pathobiology, Outcomes of Tophaceous Gout & Subclinical Inflammation in Intercritical Gout.
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
Real-World Predictors and Early Indicators for IBD in Patients With PsA
Daily Gem
Less than 10% of gout patients have crystal-proven gout.
--